19.96
price down icon0.25%   -0.05
pre-market  Pre-market:  19.80   -0.16   -0.80%
loading
Teva Pharmaceutical Industries Ltd Adr stock is traded at $19.96, with a volume of 9.33M. It is down -0.25% in the last 24 hours and up +5.33% over the past month. Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
See More
Previous Close:
$20.01
Open:
$20.02
24h Volume:
9.33M
Relative Volume:
0.84
Market Cap:
$22.89B
Revenue:
$16.70B
Net Income/Loss:
$-157.13M
P/E Ratio:
-138.04
EPS:
-0.1446
Net Cash Flow:
$1.19B
1W Performance:
+4.07%
1M Performance:
+5.33%
6M Performance:
+44.64%
1Y Performance:
+14.12%
1-Day Range:
Value
$19.87
$20.23
1-Week Range:
Value
$19.26
$20.61
52-Week Range:
Value
$12.46
$22.80

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Name
Name
Teva Pharmaceutical Industries Ltd Adr
Name
Phone
972 (3) 914-8213
Name
Address
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Name
Employee
35,686
Name
Twitter
@TevaUSA
Name
Next Earnings Date
2025-01-29
Name
Latest SEC Filings
Name
TEVA's Discussions on Twitter

Compare TEVA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
19.96 22.95B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
145.36 64.89B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.55 46.11B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
8.79 39.85B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
453.28 20.49B 3.08B 1.24B 1.07B 25.61

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-06-25 Initiated Goldman Buy
May-28-25 Initiated Truist Buy
May-12-25 Upgrade JP Morgan Neutral → Overweight
Jul-10-24 Upgrade Argus Hold → Buy
Mar-08-24 Upgrade JP Morgan Underweight → Neutral
Feb-12-24 Upgrade Piper Sandler Neutral → Overweight
Jan-23-24 Upgrade Jefferies Hold → Buy
Jan-03-24 Upgrade Piper Sandler Underweight → Neutral
Dec-18-23 Initiated HSBC Securities Buy
Nov-27-23 Upgrade UBS Neutral → Buy
Jul-06-23 Upgrade UBS Sell → Neutral
May-25-23 Initiated Morgan Stanley Equal-Weight
May-18-23 Upgrade Evercore ISI In-line → Outperform
Jan-19-23 Downgrade Jefferies Buy → Hold
Nov-14-22 Downgrade JP Morgan Neutral → Underweight
Nov-04-22 Downgrade UBS Neutral → Sell
Oct-21-22 Resumed Jefferies Buy
Aug-05-22 Upgrade BofA Securities Neutral → Buy
Jun-14-22 Resumed UBS Neutral
May-17-22 Upgrade BofA Securities Underperform → Neutral
May-04-22 Downgrade Piper Sandler Neutral → Underweight
Apr-05-22 Upgrade Barclays Equal Weight → Overweight
Mar-25-22 Upgrade Bernstein Mkt Perform → Outperform
Jan-27-22 Downgrade Argus Buy → Hold
Oct-28-21 Downgrade Raymond James Outperform → Mkt Perform
May-04-21 Downgrade UBS Buy → Neutral
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Nov-25-20 Initiated Oppenheimer Perform
Aug-06-20 Upgrade Barclays Underweight → Equal Weight
Jul-27-20 Resumed Goldman Neutral
Jun-01-20 Upgrade SunTrust Hold → Buy
Apr-24-20 Resumed Citigroup Neutral
Apr-06-20 Upgrade UBS Neutral → Buy
Feb-24-20 Downgrade Edward Jones Hold → Sell
Nov-12-19 Upgrade JP Morgan Underweight → Neutral
Oct-17-19 Upgrade Gabelli & Co Hold → Buy
Aug-07-19 Downgrade Evercore ISI Outperform → In-line
Jul-19-19 Initiated Wolfe Research Peer Perform
Jul-15-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-10-19 Resumed Credit Suisse Neutral
Jul-05-19 Upgrade Argus Hold → Buy
Jun-11-19 Initiated Barclays Underweight
Jun-03-19 Upgrade Oppenheimer Perform → Outperform
May-30-19 Downgrade BofA/Merrill Buy → Underperform
May-28-19 Downgrade UBS Buy → Neutral
Mar-20-19 Initiated SunTrust Hold
Mar-07-19 Resumed UBS Buy
View All

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News

pulisher
Oct 06, 2025

AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 06, 2025
pulisher
Oct 06, 2025

Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters - The Motley Fool

Oct 06, 2025
pulisher
Sep 21, 2025

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva

Sep 21, 2025
pulisher
Sep 20, 2025

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva

Sep 20, 2025
pulisher
Sep 16, 2025

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm

Sep 16, 2025
pulisher
Sep 14, 2025

Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World

Sep 14, 2025
pulisher
Sep 09, 2025

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva

Sep 09, 2025
pulisher
Sep 09, 2025

Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl

Sep 09, 2025
pulisher
Aug 29, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria

Aug 29, 2025
pulisher
Aug 28, 2025

Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN

Aug 28, 2025
pulisher
Aug 28, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa

Aug 28, 2025
pulisher
Aug 28, 2025

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se

Aug 28, 2025
pulisher
Aug 21, 2025

TEVA Stock Price and Chart — TASE:TEVA - TradingView

Aug 21, 2025
pulisher
Aug 21, 2025

TEVA Stock Price and Chart — NYSE:TEVA - TradingView

Aug 21, 2025
pulisher
Aug 18, 2025

Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com

Aug 18, 2025
pulisher
Aug 13, 2025

Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention - Sahm

Aug 13, 2025
pulisher
Aug 12, 2025

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Navigating a Year of Volatility - investchronicle.com

Aug 12, 2025
pulisher
Aug 06, 2025

Teva's AJOVY Receives FDA Approval for Pediatric Migraine Treatment - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Ariva

Aug 06, 2025
pulisher
Aug 04, 2025

TEVA’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com

Aug 04, 2025
pulisher
Jul 30, 2025

Teva's Pivot to Growth Strategy Underway as Innovative Portfolio Impresses and Pipeline Looks Solid - Morningstar

Jul 30, 2025
pulisher
Jul 30, 2025

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components - Ariva

Jul 30, 2025
pulisher
Jul 22, 2025

Head-To-Head Contrast: Teva Pharmaceutical Industries (NYSE:TEVA) & Taysha Gene Therapies (NASDAQ:TSHA) - Defense World

Jul 22, 2025
pulisher
Jul 16, 2025

Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Drops -2.31%, Turning Investors Away - Stocksregister

Jul 16, 2025
pulisher
Jun 26, 2025

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?26.06.25News - Ariva

Jun 26, 2025
pulisher
Jun 20, 2025

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by Yousif Capital Management LLC - Defense World

Jun 20, 2025
pulisher
Jun 17, 2025

Can Teva- Pharmaceutical Industries Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com

Jun 17, 2025
pulisher
Jun 09, 2025

Stocks Generating Improved Relative Strength: Teva Pharmaceutical ADR - MSN

Jun 09, 2025
pulisher
May 29, 2025

Teva: New Long-Term Targets and Sold Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar

May 29, 2025
pulisher
May 29, 2025

Teva: New Long-Term Targets and Solid Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar

May 29, 2025
pulisher
May 28, 2025

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance

May 28, 2025
pulisher
May 27, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

May 27, 2025
pulisher
May 20, 2025

Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart

May 20, 2025
pulisher
May 19, 2025

Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.

May 19, 2025
pulisher
May 07, 2025

Teva Earnings: Innovation Propels Sales and Generics Show Stability in Solid Start to the Year - Morningstar

May 07, 2025
pulisher
May 05, 2025

Teva and Alvotech stocks jump on FDA approval of SELARSDI - Investing.com

May 05, 2025
pulisher
May 05, 2025

Teva and Alvotech stocks jump on FDA approval of SELARSDI By Investing.com - Investing.com Canada

May 05, 2025

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$453.28
price up icon 0.05%
$139.43
price up icon 1.75%
$54.76
price up icon 4.23%
$10.13
price down icon 0.59%
drug_manufacturers_specialty_generic RDY
$14.09
price down icon 0.49%
Cap:     |  Volume (24h):